Literature DB >> 19107341

Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo.

Hiroshi Abe1, Kai Yoshizawa, Takuya Kitahara, Ryoichi Aizawa, Mika Matsuoka, Yoshio Aizawa.   

Abstract

BACKGROUND: This study was carried out to clarify the carcinogenic factors associated with nonviral hepatocellular carcinoma (HCC).
METHODS: A total of 320 HCC patients diagnosed and treated from January 2000 to December 2006 were enrolled. The clinical characteristics of non-B non-C HCC patients were examined to determine possible carcinogenic factors.
RESULTS: Of 320 HCC patients, 64 were classified as having non-B non-C HCC. The proportion of non-B non-C HCC increased from 17.8% in 2000 to 28.6% in 2006. Non-B non-C HCC patients had a significantly higher rate of early stage cirrhosis (Child-Pugh classification) than viral HCC patients. Significantly fewer non-B non-C HCC patients had periodic intensive medical assessments than viral HCC patients. Forty-five non-B non-C HCC patients were habitual alcohol drinkers, ten had nonalcoholic fatty liver disease (NAFLD), and seven had no apparent etiology. In habitual drinkers, the stage of underlying liver disease varied widely, while most NAFLD patients had early stage cirrhosis. On the other hand, more than half of the patients with HCC of undetermined etiology had noncirrhotic liver disease. Among habitual drinkers, the underlying liver disease was more progressive, and the T stage was more advanced in those with high daily alcohol intake than in those with low daily alcohol intake. Periodic intensive medical assessments were crucial for detecting early stage HCC.
CONCLUSIONS: Alcohol consumption and NAFLD may be important etiological factors in non-B non-C HCC. Periodic medical assessments for all patients with non-B non-C cirrhosis are crucial for early diagnosis and curative therapy.

Entities:  

Mesh:

Year:  2008        PMID: 19107341     DOI: 10.1007/s00535-008-2264-8

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  34 in total

1.  Detection of hepatitis B virus DNA in the liver and serum of patients with hepatitis B surface antigen and hepatitis C virus antibody negative chronic liver disease.

Authors:  Kouichi Takaguchi; Atsuhiko Satou; Masaharu Ando; Takashi Nishihara; Keiji Kita; Hiromichi Ogawa; Shosaku Hayashi; Osamu Kawamata; Takao Tsuji
Journal:  Hepatol Res       Date:  2002-02       Impact factor: 4.288

2.  Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

Authors:  P Angulo; J C Keach; K P Batts; K D Lindor
Journal:  Hepatology       Date:  1999-12       Impact factor: 17.425

3.  National prevention of hepatocellular carcinoma in Japan based on epidemiology of hepatitis C virus infection in the general population.

Authors:  Hiroshi Yoshizawa; Junko Tanaka; Yuzo Miyakawa
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

4.  Hepatocellular carcinoma associated with alcoholic liver disease: a clinicopathological study and genetic polymorphism of aldehyde dehydrogenase 2.

Authors:  M Ohhira; Y Fujimoto; A Matsumoto; T Ohtake; M Ono; Y Kohgo
Journal:  Alcohol Clin Exp Res       Date:  1996-12       Impact factor: 3.455

5.  Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.

Authors:  A Poonawala; S P Nair; P J Thuluvath
Journal:  Hepatology       Date:  2000-10       Impact factor: 17.425

6.  Clinicopathologic study on hepatocellular carcinoma negative for hepatitis B surface antigen and antibody to hepatitis C virus.

Authors:  K Noguchi; O Nakashima; Y Nakashima; K Shiota; H Nawata; M Kojiro
Journal:  Int J Mol Med       Date:  2000-12       Impact factor: 4.101

7.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

8.  Report of the 15th follow-up survey of primary liver cancer.

Authors:  Iwao Ikai; Yuji Itai; Kiwamu Okita; Masao Omata; Masamichi Kojiro; Kenichi Kobayashi; Yasuni Nakanuma; Shunji Futagawa; Masatoshi Makuuchi; Yoshio Yamaoka
Journal:  Hepatol Res       Date:  2004-01       Impact factor: 4.288

9.  Hepatocellular carcinoma arising in non-alcoholic steatohepatitis.

Authors:  Y Zen; K Katayanagi; K Tsuneyama; K Harada; I Araki; Y Nakanuma
Journal:  Pathol Int       Date:  2001-02       Impact factor: 2.534

10.  A case-control study of diabetes mellitus and cancer risk.

Authors:  C La Vecchia; E Negri; S Franceschi; B D'Avanzo; P Boyle
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

View more
  18 in total

1.  Postoperative outcomes of patients with hepatocellular carcinoma negative for all virus-related markers.

Authors:  Ichiro Yamato; Tadatoshi Takayama; Yutaka Midorikawa; Tokio Higaki; Hisashi Nakayama; Masamichi Moriguchi; Yoshiyuki Nakajima; Shunichi Matsuoka; Masahiro Ogawa; Mitsuhiko Moriyama
Journal:  Surg Today       Date:  2012-08-28       Impact factor: 2.549

2.  Clinicopathological features of hepatocellular carcinoma in patients with nonalcoholic fatty liver disease.

Authors:  Yoshihiro Mikuriya; Hirotaka Tashiro; Tsuyoshi Kobayashi; Shintaro Kuroda; Tomoyuki Abe; Masakazu Hashimoto; Hideki Ohdan
Journal:  Langenbecks Arch Surg       Date:  2015-03-06       Impact factor: 3.445

Review 3.  Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology.

Authors:  Ajay Duseja; Shivaram P Singh; Vivek A Saraswat; Subrat K Acharya; Yogesh K Chawla; Subhankar Chowdhury; Radha K Dhiman; Rohinivilasam V Jayakumar; Kaushal Madan; Sri P Misra; Hrudananda Mishra; Sunil K Modi; Arumugam Muruganathan; Banshi Saboo; Rakesh Sahay; Rajesh Upadhyay
Journal:  J Clin Exp Hepatol       Date:  2015-03-06

4.  Clinicopathological characteristics of hepatitis B surface antigen-negative and hepatitis C antibody-negative hepatocellular carcinoma.

Authors:  Hiroya Iida; Tsukasa Aihara; Shinichi Ikuta; Naoki Yamanaka
Journal:  Oncol Lett       Date:  2015-08-04       Impact factor: 2.967

5.  New insights on non-B non-C hepatocellular carcinoma in mid Delta Region, Egypt.

Authors:  Abdel Raouf Abou El Azm; Mohamed Yousef; Nagwa Mansour; Aymen Awad; Samia El Dardiry; Ibrahim Abdel Aziz
Journal:  J Gastrointest Cancer       Date:  2014-09

6.  Alcohol, postprandial plasma glucose, and prognosis of hepatocellular carcinoma.

Authors:  Hiroshi Abe; Yuta Aida; Haruya Ishiguro; Kai Yoshizawa; Tamihiro Miyazaki; Munenori Itagaki; Satoshi Sutoh; Yoshio Aizawa
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

7.  Comparison of the clinical characteristics and survival between Uyghur patients with hepatitis virus-related and non-B, non-C hepatocellular carcinoma in Xinjiang, China.

Authors:  Lei Xiao; Rui-Li Zhang; Hua Zhang; Aisiker Tulahong; Yue-Fen Zhang; Hao Wen; Yong-Xing Bao
Journal:  Chin J Cancer Res       Date:  2015-06       Impact factor: 5.087

Review 8.  Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review.

Authors:  Donna L White; Fasiha Kanwal; Hashem B El-Serag
Journal:  Clin Gastroenterol Hepatol       Date:  2012-10-04       Impact factor: 11.382

9.  Non-alcoholic Fatty Liver Disease: East Versus West.

Authors:  Swastik Agrawal; Ajay K Duseja
Journal:  J Clin Exp Hepatol       Date:  2012-07-21

10.  The impact of patatin-like phospholipase domain-containing protein 3 polymorphism on hepatocellular carcinoma prognosis.

Authors:  Yasuto Takeuchi; Fusao Ikeda; Yuki Moritou; Hiroaki Hagihara; Tetsuya Yasunaka; Kenji Kuwaki; Yasuhiro Miyake; Hideki Ohnishi; Shinichiro Nakamura; Hidenori Shiraha; Akinobu Takaki; Yoshiaki Iwasaki; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  J Gastroenterol       Date:  2012-08-07       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.